The clinical use of the Oncopet vaccine against colon cancer began in Russia.
The drug was developed on the basis of neoantigens of a patient's specific cancer cells and has already been registered. Now FMBA is recruiting patients for its clinical use, said the deputy head of the agency Igor Borisevich.
Another mRNA vaccine, FMBA, for the treatment of glioblastoma, a malignant brain tumor, is registered. The documents are under review by the Russian Ministry of Health.